CW December 2003
Volume 12Issue Number 12 December 2003 ISSN 10593802 How Long Will Imatinib-Treated CML Patients Live?More than half of chronic myeloid leukemia (CML) patients treated with imatinib will survive for at least 10 years, twice as many as those treated with interferon, according to current prognostic indicators and several recent reports.
Go to Previous Page Go to Next Page Source & Additional Reading J. Hasford, American Society of Hematology Annual Meeting in San Diego. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW December 2003Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
